Research ArticlesPrecursor-dependent indirect pharmacodynamic response model for tolerance and rebound phenomena†
References and Notes (18)
- et al.
Beta-adrenergic blocker withdrawal syndromes in hypertension and other cardiovascular diseases
Am. Heart J.
(1988) - et al.
A program package for simulation and parameter estimation in pharmacokinetic systems
Comp. Programs Biomed.
(1979) - et al.
Integrated functions for four basic models of indirect pharmacodynamic response
J. Pharm. Sci.
(1998) - et al.
Transit compartments versus gamma distribution function to model signal transduction processes in pharmacodynamics
J. Pharm. Sci.
(1998) - et al.
Molecular mechanisms of receptor desensitization using the β-adrenergic receptor-coupled adenylate cyclase system as a model
Nature
(1985) - et al.
Drug- or hormone-induced adaptation: model of adrenergic hypersensitivity
J. Pharmacokin. Biopharm.
(1989) - et al.
Molecular pharmacology: The mode of action of biologically active compounds
Blood pressure control-special role of the kidneys and body fluids
Science
(1991)- et al.
Prolactin release after remoxipride by an integrated pharmacokinetic-pharmacodynamic model with intra- and inter-individual aspects
J. Pharmacol. Exp. Ther.
(1995)
Cited by (108)
The Physiological and Pharmacological Significance of the Circadian Timing of the HPA Axis: A Mathematical Modeling Approach
2024, Journal of Pharmaceutical SciencesSystems pharmacology – Towards the modeling of network interactions
2016, European Journal of Pharmaceutical SciencesCitation Excerpt :In their most basic form these models are based on the concept of a physiological indirect response or turnover model as originally proposed by Levy to describe the time course of the anticoagulant effect of warfarin (Nagashima et al., 1969). Jusko et al. have subsequently formalized the concept of using various forms of a turnover model to characterize time-dependencies in the pharmacodynamics of a wide range of drugs (Dayneka et al., 1993; Jusko, 1995; Jusko and Ko, 1994; Sharma et al., 1998). Here, the drug effect is being characterized as an enhancing or inhibiting effect on either the zero order rate constant for input in the system or the first order rate constant for elimination from the system (Dayneka et al., 1993).
Model-Based Virtual PK/PD Exploration and Machine Learning Approach to Define PK Drivers in Early Drug Discovery
2024, Journal of Medicinal ChemistryPharmacodynamic Biomarkers for Biosimilar Development and Approval: A Workshop Summary
2023, Clinical Pharmacology and Therapeutics
- †
Supported in part by Grant No. 24211 from the National Institute of General Medical Science, National Institutes of Health.